Stopping Trials Early for Benefit—Not So Fast

On October 25, 2011, Eli Lilly and Company announced the voluntary withdrawal of Xigris (drotrecogin alfa [activated]) following the negative results of its most recent clinical trial, the PROWESS-SHOCK study. The purpose of this commentary is to briefly review the history of drotrecogin alfa, discu...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2012-11, Vol.46 (11), p.1564-1567
Main Authors: Faust, Andrew C, Chung, Tammy, Feldman, Mark
Format: Article
Language:English
Subjects:
Anti-Infective Agents - therapeutic use
Biological and medical sciences
Clinical trial. Drug monitoring
General pharmacology
Humans
Medical sciences
Pharmacology. Drug treatments
Protein C - therapeutic use
Randomized Controlled Trials as Topic
Recombinant Proteins - therapeutic use
Sepsis - drug therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3
cites cdi_FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3
container_end_page 1567
container_issue 11
container_start_page 1564
container_title The Annals of pharmacotherapy
container_volume 46
creator Faust, Andrew C
Chung, Tammy
Feldman, Mark
description On October 25, 2011, Eli Lilly and Company announced the voluntary withdrawal of Xigris (drotrecogin alfa [activated]) following the negative results of its most recent clinical trial, the PROWESS-SHOCK study. The purpose of this commentary is to briefly review the history of drotrecogin alfa, discuss issues surrounding early cessation of clinical trials for benefit, and highlight the scientific and ethical dilemmas faced when deciding whether or not to stop a trial early for benefit. This review should serve as an introduction to the topic of stopping trials early for benefit.
doi_str_mv 10.1345/aph.1Q780
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1151917012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1Q780</sage_id><sourcerecordid>1151917012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3</originalsourceid><addsrcrecordid>eNpt0LFOwzAQgGELgWgpDLwAygKCIa0vdhxnhKoFpAqEWubIceySKo2DnQzdeAiekCfB0AILk2_4dGf9CJ0CHgKh8Ug0L0N4SjjeQ32IaRSyKMH7fsYMhzjiuIeOnFthjFOI0kPUiwgQRmLaR6N5a5qmrJfBwpaicsFE2GoTaGODG1UrXbYfb-8Ppg3mJpgK1x6jA-2ZOtm9A_Q8nSzGd-Hs8fZ-fD0LJaGsDSlnUNC4iFMgmCvgRarjnKhCcC20TFnuP54LSTWBgkeJyCWmAjijOZdc5mSALrd7G2teO-XabF06qapK1Mp0LgOIIYUEQ-Tp1ZZKa5yzSmeNLdfCbjLA2VefzPfJvvt4e7Zb2-VrVfzKnyAenO-AcFJU2opalu7PMX-S8cS7i61zYqmylels7XP8c_ETikR5Fg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1151917012</pqid></control><display><type>article</type><title>Stopping Trials Early for Benefit—Not So Fast</title><source>SAGE</source><creator>Faust, Andrew C ; Chung, Tammy ; Feldman, Mark</creator><creatorcontrib>Faust, Andrew C ; Chung, Tammy ; Feldman, Mark</creatorcontrib><description>On October 25, 2011, Eli Lilly and Company announced the voluntary withdrawal of Xigris (drotrecogin alfa [activated]) following the negative results of its most recent clinical trial, the PROWESS-SHOCK study. The purpose of this commentary is to briefly review the history of drotrecogin alfa, discuss issues surrounding early cessation of clinical trials for benefit, and highlight the scientific and ethical dilemmas faced when deciding whether or not to stop a trial early for benefit. This review should serve as an introduction to the topic of stopping trials early for benefit.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1Q780</identifier><identifier>PMID: 23136354</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Anti-Infective Agents - therapeutic use ; Biological and medical sciences ; Clinical trial. Drug monitoring ; General pharmacology ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Protein C - therapeutic use ; Randomized Controlled Trials as Topic ; Recombinant Proteins - therapeutic use ; Sepsis - drug therapy ; Treatment Outcome</subject><ispartof>The Annals of pharmacotherapy, 2012-11, Vol.46 (11), p.1564-1567</ispartof><rights>2012 SAGE Publications</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3</citedby><cites>FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26701687$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23136354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faust, Andrew C</creatorcontrib><creatorcontrib>Chung, Tammy</creatorcontrib><creatorcontrib>Feldman, Mark</creatorcontrib><title>Stopping Trials Early for Benefit—Not So Fast</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>On October 25, 2011, Eli Lilly and Company announced the voluntary withdrawal of Xigris (drotrecogin alfa [activated]) following the negative results of its most recent clinical trial, the PROWESS-SHOCK study. The purpose of this commentary is to briefly review the history of drotrecogin alfa, discuss issues surrounding early cessation of clinical trials for benefit, and highlight the scientific and ethical dilemmas faced when deciding whether or not to stop a trial early for benefit. This review should serve as an introduction to the topic of stopping trials early for benefit.</description><subject>Anti-Infective Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical trial. Drug monitoring</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein C - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Sepsis - drug therapy</subject><subject>Treatment Outcome</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpt0LFOwzAQgGELgWgpDLwAygKCIa0vdhxnhKoFpAqEWubIceySKo2DnQzdeAiekCfB0AILk2_4dGf9CJ0CHgKh8Ug0L0N4SjjeQ32IaRSyKMH7fsYMhzjiuIeOnFthjFOI0kPUiwgQRmLaR6N5a5qmrJfBwpaicsFE2GoTaGODG1UrXbYfb-8Ppg3mJpgK1x6jA-2ZOtm9A_Q8nSzGd-Hs8fZ-fD0LJaGsDSlnUNC4iFMgmCvgRarjnKhCcC20TFnuP54LSTWBgkeJyCWmAjijOZdc5mSALrd7G2teO-XabF06qapK1Mp0LgOIIYUEQ-Tp1ZZKa5yzSmeNLdfCbjLA2VefzPfJvvt4e7Zb2-VrVfzKnyAenO-AcFJU2opalu7PMX-S8cS7i61zYqmylels7XP8c_ETikR5Fg</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Faust, Andrew C</creator><creator>Chung, Tammy</creator><creator>Feldman, Mark</creator><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121101</creationdate><title>Stopping Trials Early for Benefit—Not So Fast</title><author>Faust, Andrew C ; Chung, Tammy ; Feldman, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-Infective Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical trial. Drug monitoring</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein C - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Sepsis - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faust, Andrew C</creatorcontrib><creatorcontrib>Chung, Tammy</creatorcontrib><creatorcontrib>Feldman, Mark</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faust, Andrew C</au><au>Chung, Tammy</au><au>Feldman, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stopping Trials Early for Benefit—Not So Fast</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>46</volume><issue>11</issue><spage>1564</spage><epage>1567</epage><pages>1564-1567</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>On October 25, 2011, Eli Lilly and Company announced the voluntary withdrawal of Xigris (drotrecogin alfa [activated]) following the negative results of its most recent clinical trial, the PROWESS-SHOCK study. The purpose of this commentary is to briefly review the history of drotrecogin alfa, discuss issues surrounding early cessation of clinical trials for benefit, and highlight the scientific and ethical dilemmas faced when deciding whether or not to stop a trial early for benefit. This review should serve as an introduction to the topic of stopping trials early for benefit.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>23136354</pmid><doi>10.1345/aph.1Q780</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1060-0280
ispartof The Annals of pharmacotherapy, 2012-11, Vol.46 (11), p.1564-1567
issn 1060-0280
1542-6270
language eng
recordid cdi_proquest_miscellaneous_1151917012
source SAGE
subjects Anti-Infective Agents - therapeutic use
Biological and medical sciences
Clinical trial. Drug monitoring
General pharmacology
Humans
Medical sciences
Pharmacology. Drug treatments
Protein C - therapeutic use
Randomized Controlled Trials as Topic
Recombinant Proteins - therapeutic use
Sepsis - drug therapy
Treatment Outcome
title Stopping Trials Early for Benefit—Not So Fast
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A00%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stopping%20Trials%20Early%20for%20Benefit%E2%80%94Not%20So%20Fast&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Faust,%20Andrew%20C&rft.date=2012-11-01&rft.volume=46&rft.issue=11&rft.spage=1564&rft.epage=1567&rft.pages=1564-1567&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1Q780&rft_dat=%3Cproquest_cross%3E1151917012%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c346t-4861d45d591308e18d9f5b3eda8fafc96b134bac4f31d827abc04a1864b8c8cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1151917012&rft_id=info:pmid/23136354&rft_sage_id=10.1345_aph.1Q780&rfr_iscdi=true